Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THERANOVA: Theranostic Agents in Solid Tumors with Brain Metastases
NCT07178938Phase 2Not yet recruiting
- Sponsor
- MEDSIR
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Peptides
01
Overview
A Phase 2 trial of gallium Ga 68-edotreotide in HER2-positive breast cancer, brain metastases, sponsored by MEDSIR. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
HER2-positive breast cancerbrain metastases
Beyond the preview
Go deeper on NCT07178938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178938.